{
    "clinical_study": {
        "@rank": "40115", 
        "acronym": "TIV_HIV_TB", 
        "arm_group": {
            "arm_group_label": "TIV", 
            "arm_group_type": "Other", 
            "description": "Trivalent Inactivated Influenza Vaccine The study vaccine will be the seasonal 2013 un-adjuvanted TIV which is provided as a 0\u20225 milliliter suspension of split virus mixture of 15 micrograms each of circulating H1N1- like strain, H3N2- like strain and B - like strain.\nThe WHO recommended vaccine formulation for Southern Hemisphere 2013 Influenza Season contains the following influenza strains:\nA/California/7/2009 (H1N1)pdm-like virus\nA/Victoria/361/2011 (H3N2)-like virus\nB/Wisconsin/1/2010-like virus. (Yamagata lineage)"
        }, 
        "brief_summary": {
            "textblock": "Prospective, open-labelled study which will enrol 360 participants in four groups of 80\n      participants including: HIV-uninfected adults without evidence of TB; HIV-infected adults\n      without any evidence of TB; HIV-uninfected adults with concurrent microbiologic confirmed\n      TB, HIV-infected adults with concurrent microbiologic confirmed TB.\n\n      Participants will receive the recommended seasonal 2013 un-adjuvanted Trivalent Influenza\n      Vaccine (TIV). At 3 visits, blood will be collected for determination of immune responses.\n\n      Objective:\n\n      \u2022 To determine the effect of HIV-infection, tuberculosis (TB) and HIV-TB co-infection on\n      immune responses"
        }, 
        "brief_title": "Effect of HIV and/or Active Tuberculosis on the Immune Responses to Trivalent Influenza Vaccine (TIV) in Adults", 
        "completion_date": {
            "#text": "December 2014", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Influenza", 
            "HIV", 
            "Tuberculosis"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Influenza, Human", 
                "Tuberculosis"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  for HIV-infected subjects: a  Cluster of Differntiation4 (CD4+) cell count of >100/ul\n             within the previous 3 months;\n\n          -  able to attend the clinic for immunogenicity and illness visits;\n\n          -  for subjects with TB: having a microbiologic confirmed diagnosis of TB  (defined as\n             the presence of acid-fast-bacilli (AFB) on a sputum smear or other specimen and/or a\n             positive culture for M. tuberculosis) within the past 120 days;\n\n          -  Aged 18 to 55 years.\n\n        Exclusion Criteria:\n\n          -  any contraindication to influenza vaccine;\n\n          -  any contraindication to intramuscular injections;\n\n          -  any existing grade 3 or grade 4 laboratory or clinical toxicity as per Division of\n             Acquired Immune Deficiency Syndrome (DAIDS) toxicity tables;\n\n          -  systemic steroid treatment for >21 days within the past 30 days.\n\n          -  pregnancy (a urine Human Chorionic Gonadotropin (\u03b2HCG) will be performed on all women\n             of childbearing age to exclude pregnancy)"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "55 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "360", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "February 21, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01811823", 
            "org_study_id": "TIV_HIV_TB"
        }, 
        "intervention": {
            "arm_group_label": "TIV", 
            "description": "The study vaccine will be the seasonal 2013 un-adjuvanted TIV which is provided as a 0\u20225 milliliter suspension of split virus mixture of 15 micrograms each of circulating H1N1- like strain, H3N2- like strain and B - like strain.\nThe WHO recommended vaccine formulation for Southern Hemisphere 2013 Influenza Season contains the following influenza strains:\nA/California/7/2009 (H1N1)pdm-like virus\nA/Victoria/361/2011 (H3N2)-like virus\nB/Wisconsin/1/2010-like virus. (Yamagata lineage)", 
            "intervention_name": "Trivalent Inactivated Influenza Vaccine", 
            "intervention_type": "Biological", 
            "other_name": "Vaxigrip"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Tuberculosis", 
            "HIV infection", 
            "Immune responses to Influenza vaccination"
        ], 
        "lastchanged_date": "December 10, 2013", 
        "location": {
            "facility": {
                "address": {
                    "city": "Soweto, Johannesburg", 
                    "country": "South Africa", 
                    "state": "Gauteng", 
                    "zip": "2013"
                }, 
                "name": "Respiratory and Meningeal Pathogens research unit"
            }, 
            "investigator": [
                {
                    "last_name": "Stephanie Jones, MD", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "Anthonet L Koen, MD", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "Clare L Cutland, MD", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "Niresha Govender, MD", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "Lisa Jose, MD", 
                    "role": "Sub-Investigator"
                }
            ], 
            "status": "Not yet recruiting"
        }, 
        "location_countries": {
            "country": "South Africa"
        }, 
        "number_of_arms": "1", 
        "official_title": "Effect of HIV and/or Active Tuberculosis on the Humoral and Cell Mediated Immune Responses to Un-adjuvanted Trivalent Sub-unit Influenza Vaccine (TIV) in Adults", 
        "overall_official": {
            "affiliation": "University of the Witwatersrand", 
            "last_name": "Shabir A Madhi, PHD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": "South Africa: Human Research Ethics Committee", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 4", 
        "primary_completion_date": {
            "#text": "December 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "\u2022\tTo determine the effect of HIV-infection, tuberculosis (TB) and HIV-TB co-infection on humoral antibody responses, measured by hemagglutinin inhibition assay (HAI), to each of three strains included in the seasonal non-adjuvanted trivalent influenza vaccine In this study we will use the following definitions to assess the humoral immune response to TIV: HAI titers <1:10 = seronegative; HAI titers \u22651:10 = seropositive; HAI titers \u22651:40 = sero-protective; sero-response rate (primary outcome measure) will be defined as a titer of \u22651:40 in an individual with baseline titers of <1:10, or >4-fold increase of HAI titers if baseline titers were \u22651:10. Hemagglutination inhibition assays will be performed on serum as per recommended methods. Sera will be titrated against antigens from the influenza vaccine strains included in the 2013 seasonal TIV.", 
            "measure": "humoral antibody responses, measured by hemagglutinin inhibition assay (HAI), to each of three strains included in the seasonal non-adjuvanted trivalent influenza vaccine.", 
            "safety_issue": "No", 
            "time_frame": "up to 6 weeks after end of the influenza season"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01811823"
        }, 
        "responsible_party": {
            "investigator_affiliation": "University of Witwatersrand, South Africa", 
            "investigator_full_name": "Michelle Groome", 
            "investigator_title": "Dr", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": {
            "description": "\u2022 To compare the effect of HIV-infection, tuberculosis (TB) and HIV-TB co-infection on vaccine-strain specific cell mediated immune responses, evaluated by Enzyme-linked immunosorbent spot (ELISPOT) assay, following non-adjuvanted TIV vaccination.\nThe cell mediated Immunity (CMI) evaluations in this study will provide novel information on influenza-specific CMI in individuals with TB. Interferon gama- ELISPOT responses will be assessed on fresh Peripheral Blood Mononuclear Cells (PBMCs). Spots will be visualized with a ELISPOT plate reader. Background (non-specific) spots detected in the medium-containing wells will be subtracted from the wells stimulated with influenza antigens. Results will be reported as Spot forming cell (SFC)/106 PBMCs.", 
            "measure": "\u2022 To compare the effect of HIV-infection, tuberculosis (TB) and HIV-TB co-infection on vaccine-strain specific cell mediated immune responses, evaluated by ELISPOT assay, following non-adjuvanted TIV vaccination.", 
            "safety_issue": "No", 
            "time_frame": "up to 6 weeks after the end of the influenza season"
        }, 
        "source": "University of Witwatersrand, South Africa", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "University of Witwatersrand, South Africa", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "March 2014", 
        "study_design": "Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science", 
        "study_type": "Interventional", 
        "verification_date": "December 2013"
    }
}